O	0	6	Effect
O	7	9	of
B-intervention	10	19	letrozole
O	20	26	versus
B-control	27	34	placebo
O	35	37	on
O	38	42	bone
O	43	50	mineral
O	51	58	density
O	59	61	in
O	62	67	women
B-eligibility	68	72	with
I-eligibility	73	80	primary
I-eligibility	81	87	breast
I-eligibility	88	94	cancer
I-eligibility	95	105	completing
I-eligibility	106	107	5
I-eligibility	108	110	or
I-eligibility	111	115	more
I-eligibility	116	121	years
I-eligibility	122	124	of
I-eligibility	125	133	adjuvant
I-eligibility	134	143	tamoxifen
O	143	144	:
O	145	146	a
O	147	156	companion
O	157	162	study
O	163	165	to
O	166	170	NCIC
O	171	174	CTG
O	175	177	MA
O	177	178	.
O	178	180	17
O	180	181	.

O	182	191	Aromatase
O	192	202	inhibition
O	203	211	depletes
O	212	220	estrogen
O	221	227	levels
O	228	231	and
O	232	235	may
O	236	238	be
O	239	249	associated
O	250	254	with
O	255	266	accelerated
O	267	271	bone
O	272	282	resorption
O	282	283	.

O	284	287	The
O	288	296	National
O	297	303	Cancer
O	304	313	Institute
O	314	316	of
B-location	317	323	Canada
O	324	332	Clinical
O	333	339	Trials
O	340	345	Group
O	346	347	(
O	347	351	NCIC
O	352	355	CTG
O	355	356	)
O	357	362	study
O	363	365	MA
O	365	366	.
O	366	369	17B
O	370	379	evaluated
O	380	384	bone
O	385	393	turnover
O	394	401	markers
O	402	405	and
O	406	410	bone
O	411	418	mineral
O	419	426	density
O	427	428	(
O	428	431	BMD
O	431	432	)
O	433	435	in
O	436	450	postmenopausal
O	451	456	women
O	457	465	randomly
O	466	474	assigned
O	475	477	to
O	478	480	MA
O	480	481	.
O	481	483	17
O	483	484	,
O	485	486	a
O	487	494	placebo
O	494	495	-
O	495	505	controlled
O	506	511	trial
O	512	514	of
O	515	524	letrozole
O	525	530	after
O	531	539	standard
O	540	548	adjuvant
O	549	558	tamoxifen
O	558	559	.

O	560	568	Eligible
O	569	574	women
O	575	578	had
O	579	580	a
O	581	589	baseline
O	590	593	BMD
O	594	595	T
O	596	601	score
O	602	604	of
O	605	607	at
O	608	613	least
O	614	615	2
O	615	616	.
O	616	617	0
O	618	620	in
O	621	627	either
O	628	631	the
O	632	635	hip
O	636	638	or
O	639	641	L2
O	641	642	-
O	642	643	4
O	644	649	spine
O	649	650	;
O	651	654	all
O	655	663	received
O	664	671	calcium
O	672	675	500
O	676	678	mg
O	679	682	and
O	683	690	vitamin
O	691	692	D
O	693	696	400
O	697	698	U
O	699	704	daily
O	704	705	.

O	706	716	Percentage
O	717	723	change
O	724	726	in
O	727	730	BMD
O	731	732	(
O	732	734	L2
O	734	735	-
O	735	737	L4
O	738	743	spine
O	744	747	and
O	748	751	hip
O	751	752	)
O	753	755	at
O	756	758	12
O	759	762	and
O	763	765	24
O	766	772	months
O	772	773	,
O	774	778	rate
O	779	781	of
O	782	794	osteoporosis
O	794	795	,
O	796	799	and
O	800	806	change
O	807	809	in
O	810	817	markers
O	818	820	of
O	821	825	bone
O	826	835	formation
O	836	837	(
O	837	842	serum
O	843	847	bone
O	848	856	alkaline
O	857	868	phosphatase
O	868	869	)
O	870	873	and
O	874	884	resorption
O	885	886	(
O	886	891	serum
O	892	893	C
O	893	894	-
O	894	905	telopeptide
O	906	909	and
O	910	915	urine
O	916	917	N
O	917	918	-
O	918	929	telopeptide
O	929	930	)
O	931	933	at
O	934	935	6
O	935	936	,
O	937	939	12
O	939	940	,
O	941	944	and
O	945	947	24
O	948	954	months
O	955	959	were
O	960	968	compared
O	968	969	.

B-total-participants	970	973	Two
I-total-participants	974	981	hundred
I-total-participants	982	988	twenty
I-total-participants	988	989	-
I-total-participants	989	992	six
O	993	1001	patients
O	1002	1003	(
B-intervention-participants	1003	1006	122
O	1007	1016	letrozole
O	1016	1017	,
B-control-participants	1018	1021	104
O	1022	1029	placebo
O	1029	1030	)
O	1031	1035	were
O	1036	1044	enrolled
O	1044	1045	.

O	1046	1054	Baseline
O	1055	1070	characteristics
O	1071	1075	were
O	1076	1083	similar
O	1084	1086	in
O	1087	1090	the
O	1091	1094	two
O	1095	1101	groups
O	1101	1102	,
O	1103	1112	including
O	1113	1116	BMD
O	1116	1117	,
O	1118	1124	median
O	1125	1128	age
O	1129	1131	of
B-age	1132	1134	60
I-age	1134	1135	.
I-age	1135	1136	7
I-age	1137	1142	years
O	1143	1144	(
O	1144	1146	81
O	1146	1147	%
O	1148	1149	<
O	1150	1152	70
O	1153	1158	years
O	1158	1159	)
O	1159	1160	,
O	1161	1164	and
O	1165	1171	median
O	1172	1178	follow
O	1178	1179	-
O	1179	1181	up
O	1182	1184	of
O	1185	1186	1
O	1186	1187	.
O	1187	1188	6
O	1189	1194	years
O	1194	1195	.

O	1196	1198	At
O	1199	1201	24
O	1202	1208	months
O	1208	1209	,
O	1210	1218	patients
O	1219	1228	receiving
O	1229	1238	letrozole
O	1239	1242	had
O	1243	1244	a
O	1245	1256	significant
O	1257	1265	decrease
O	1266	1268	in
B-outcome	1269	1274	total
I-outcome	1275	1278	hip
I-outcome	1279	1282	BMD
O	1283	1284	(
B-iv-cont-mean	1284	1285	-
I-iv-cont-mean	1285	1286	3
I-iv-cont-mean	1286	1287	.
I-iv-cont-mean	1287	1288	6
I-iv-cont-mean	1288	1289	%
O	1290	1291	v
B-cv-cont-mean	1292	1293	-
I-cv-cont-mean	1293	1294	0
I-cv-cont-mean	1294	1295	.
I-cv-cont-mean	1295	1297	71
I-cv-cont-mean	1297	1298	%
O	1298	1299	;
O	1300	1301	P
O	1302	1303	=
O	1304	1305	.
O	1305	1308	044
O	1308	1309	)
O	1310	1313	and
B-outcome	1314	1320	lumbar
I-outcome	1321	1326	spine
I-outcome	1327	1330	BMD
O	1331	1332	(
B-iv-cont-mean	1332	1333	-
I-iv-cont-mean	1333	1334	5
I-iv-cont-mean	1334	1335	.
I-iv-cont-mean	1335	1337	35
I-iv-cont-mean	1337	1338	%
O	1339	1340	v
B-cv-cont-mean	1341	1342	-
I-cv-cont-mean	1342	1343	0
I-cv-cont-mean	1343	1344	.
I-cv-cont-mean	1344	1346	70
I-cv-cont-mean	1346	1347	%
O	1347	1348	;
O	1349	1350	P
O	1351	1352	=
O	1353	1354	.
O	1354	1357	008
O	1357	1358	)
O	1358	1359	.

O	1360	1369	Letrozole
O	1370	1379	increased
B-outcome	1380	1385	urine
I-outcome	1386	1387	N
I-outcome	1387	1388	-
I-outcome	1388	1399	telopeptide
I-outcome	1400	1402	at
I-outcome	1403	1404	6
I-outcome	1404	1405	,
I-outcome	1406	1408	12
I-outcome	1408	1409	,
I-outcome	1410	1413	and
I-outcome	1414	1416	24
I-outcome	1417	1423	months
O	1424	1425	(
O	1425	1426	P
O	1427	1428	=
O	1429	1430	.
O	1430	1433	054
O	1433	1434	,
O	1435	1436	<
O	1437	1438	.
O	1438	1441	001
O	1441	1442	,
O	1443	1446	and
O	1447	1448	.
O	1448	1451	016
O	1451	1452	,
O	1453	1465	respectively
O	1465	1466	)
O	1466	1467	.

O	1468	1470	No
O	1471	1478	patient
O	1479	1483	went
O	1484	1489	below
O	1490	1493	the
O	1494	1503	threshold
O	1504	1507	for
O	1508	1520	osteoporosis
O	1521	1523	in
B-outcome	1524	1529	total
I-outcome	1530	1533	hip
I-outcome	1534	1537	BMD
O	1537	1538	,
O	1539	1546	whereas
O	1547	1549	at
O	1550	1553	the
O	1554	1556	L2
O	1556	1557	-
O	1557	1559	L4
O	1560	1561	(
O	1561	1576	posteroanterior
O	1577	1581	view
O	1581	1582	)
O	1582	1583	,
O	1584	1588	more
O	1589	1594	women
O	1595	1601	became
B-outcome	1602	1614	osteoporotic
I-outcome	1615	1617	by
I-outcome	1618	1621	BMD
O	1622	1627	while
O	1628	1637	receiving
O	1638	1647	letrozole
O	1648	1649	(
B-iv-bin-percent	1649	1650	4
I-iv-bin-percent	1650	1651	.
I-iv-bin-percent	1651	1652	1
I-iv-bin-percent	1652	1653	%
O	1654	1655	v
B-cv-bin-percent	1656	1657	0
I-cv-bin-percent	1657	1658	%
O	1658	1659	;
O	1660	1661	P
O	1662	1663	=
O	1664	1665	.
O	1665	1668	064
O	1668	1669	)
O	1669	1670	.

O	1671	1676	After
O	1677	1678	5
O	1679	1684	years
O	1685	1687	of
O	1688	1696	adjuvant
O	1697	1706	tamoxifen
O	1706	1707	,
O	1708	1718	subsequent
O	1719	1728	letrozole
O	1729	1735	causes
O	1736	1737	a
O	1738	1744	modest
O	1745	1753	increase
O	1754	1756	in
O	1757	1761	bone
O	1762	1772	resorption
O	1773	1776	and
O	1777	1786	reduction
O	1787	1789	in
O	1790	1794	bone
O	1795	1802	mineral
O	1803	1810	density
O	1811	1813	in
O	1814	1817	the
O	1818	1823	spine
O	1824	1827	and
O	1828	1831	hip
O	1832	1840	compared
O	1841	1843	to
O	1844	1851	placebo
O	1851	1852	.

O	1853	1860	Further
O	1861	1867	follow
O	1867	1868	-
O	1868	1870	up
O	1871	1873	is
O	1874	1883	necessary
O	1884	1886	to
O	1887	1895	evaluate
O	1896	1899	the
O	1900	1904	long
O	1904	1905	-
O	1905	1909	term
O	1910	1918	clinical
O	1919	1931	implications
O	1932	1934	of
O	1935	1939	this
O	1940	1950	difference
O	1950	1951	.
